Gilead Sciences (GILD)

Asegua Therapeutics LLC • CymaBay Therapeutics, Inc. • Forty Seven, LLC • Forty Seven Holdings, LLC • Gilead Alberta, LLC • Gilead Apollo, LLC • Gilead Biopharmaceutics US LLC • Gilead Calistoga, LLC • Gilead Connecticut, Inc. • Gilead Holdings, LLC ...

IRS number

943047598

GILD stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$110.33

Low target

$90.00

High target

$123.00

Latest filings (excl ownership)

View all

28 Feb 25

Gilead Sciences Announces Fourth Quarter and Full Year 2024 Financial Results

11 Feb 25

8-K/A

Departure of Directors or Certain Officers

12 Dec 24

8-K

Entry into a Material Definitive Agreement

20 Nov 24

424B5

Prospectus supplement for primary offering

15 Nov 24

FWP

Free writing prospectus

13 Nov 24

424B5

Prospectus supplement for primary offering

12 Nov 24

Gilead Sciences Announces Third Quarter 2024 Financial Results

8 Aug 24

Transcripts

View all

GILD

Earnings call transcript

2024 Q4

11 Feb 25

GILD

Earnings call transcript

2024 Q3

6 Nov 24

GILD

Earnings call transcript

2024 Q2

8 Aug 24

GILD

Earnings call transcript

2024 Q1

25 Apr 24

GILD

Earnings call transcript

2023 Q4

6 Feb 24

GILD

Earnings call transcript

2023 Q3

7 Nov 23

GILD

Earnings call transcript

2023 Q2

3 Aug 23

GILD

Earnings call transcript

2023 Q2

3 Aug 23

GILD

Earnings call transcript

2023 Q1

27 Apr 23

GILD

Earnings call transcript

2022 Q4

2 Feb 23

Latest ownership filings

View all

SC 13D/A

Arcus Biosciences, Inc.

20 Feb 25

Arcus Biosciences, Inc.

Notice of proposed sale of securities

Quarterly holdings report by institutional manager

13 Feb 25

144

Notice of proposed sale of securities

Financial summary

Financial statements Chart GILD financial data

Quarter (USD)	Dec 24	Sep 24	Jun 24	Mar 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q4 2024

GILD institutional ownership history Ownership history

84.9% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	1825	1701	+7.3%
Opened positions	263	172	+52.9%
Closed positions	139	133	+4.5%
Increased positions	628	612	+2.6%
Reduced positions	706	687	+2.8%

13F shares	Current	Prev Q	Change
Total value	93.86 tn	82.28 tn	+14.1%
Total shares	1.06 bn	1.03 bn	+3.1%
Total puts	8.98 mm	9.73 mm	-7.7%
Total calls	8.33 mm	10.32 mm	-19.2%
Total put/call ratio	1.1	0.9	+14.2%

Largest owners	Shares	Value	Change
BlackRock	120.36 mm	$11.12 tn	-1.3%
Vanguard	115.53 mm	$10.67 tn	+0.2%
Capital World Investors	71.71 mm	$6.62 tn	-6.3%
STT State Street	60.38 mm	$5.58 tn	+0.3%
Capital Research Global Investors	57.95 mm	$5.35 tn	-6.2%
FMR	40.32 mm	$3.72 tn	+21.6%
Wellington Management	35.66 mm	$3.29 tn	+3.1%
Dodge & Cox	32.95 mm	$3.04 tn	-0.3%
Geode Capital Management	28.29 mm	$2.61 tn	+2.7%
MS Morgan Stanley	20.07 mm	$1.85 tn	+16.4%

Largest transactions	Shares	Bought/sold	Change
Norges Bank	19.37 mm	+19.37 mm	NEW
BAC Bank of America	17.72 mm	+10.49 mm	+145.1%
FMR	40.32 mm	+7.16 mm	+21.6%
Pacer Advisors	6.43 mm	+5.65 mm	+723.3%
Capital World Investors	71.71 mm	-4.84 mm	-6.3%
Amundi	9.02 mm	-4.60 mm	-33.8%
Capital Research Global Investors	57.95 mm	-3.85 mm	-6.2%
Arrowstreet Capital, Limited Partnership	139.61 k	-2.86 mm	-95.3%
BK The Bank of New York Mellon Corporation	16.76 mm	+2.83 mm	+20.3%
MS Morgan Stanley	20.07 mm	+2.82 mm	+16.4%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

GILD insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
18 Feb 25	Dickinson Andrew D	Common Stock	Sell	Dispose S	No	Yes	104.09	2,500	260.23 k	169,061
18 Feb 25	Gilead Sciences	Common Stock	Buy	Acquire P	No	No	11	1,363,636	15.00 mm	31,424,760
12 Feb 25	Dickinson Andrew D	Common Stock	Sell	Dispose S	No	Yes	102.22	137,676	14.07 mm	171,223
12 Feb 25	Dickinson Andrew D	Common Stock	Option exercise	Acquire M	No	Yes	83.49	18,210	1.52 mm	308,899
12 Feb 25	Dickinson Andrew D	Common Stock	Option exercise	Acquire M	No	Yes	80.72	15,600	1.26 mm	290,689
12 Feb 25	Dickinson Andrew D	Common Stock	Option exercise	Acquire M	No	Yes	57.92	26,175	1.52 mm	275,089
12 Feb 25	Dickinson Andrew D	Common Stock	Option exercise	Acquire M	No	Yes	63.91	77,691	4.97 mm	248,914
12 Feb 25	Dickinson Andrew D	NQSO Common Stock	Option exercise	Dispose M	No	Yes	83.49	18,210	1.52 mm	0
12 Feb 25	Dickinson Andrew D	NQSO Common Stock	Option exercise	Dispose M	No	Yes	80.72	15,600	1.26 mm	0
12 Feb 25	Dickinson Andrew D	NQSO Common Stock	Option exercise	Dispose M	No	Yes	57.92	26,175	1.52 mm	78,515